3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Polycystic Ovary Syndrome
3
Motor Activity
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Sarcopenia
1
Recurrence
1
Prostatic Neoplasms
1
Patient Compliance
1
Pancreatitis, Chronic
1
Pancreatic Neoplasms
1
Obesity
1
Duodenal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Diet
×
Clear all
NCT02035631
2014-01-14
PREDICOP
Institut Català d'Oncologia
Phase 3
Unknown
2,000 enrolled